MedTrace Logo

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

NCT01783834 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2016-02-11

No results posted yet for this study

Summary

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

Conditions

  • Previous Treated Metastatic Non-small Cell Lung Cancer

Interventions

DRUG

Gefitinib

compare progression free survivla rate and safety to both drugs

DRUG

Pemetrexed

compare PFS rate, safety to both drugs

Sponsors & Collaborators

  • Gachon University Gil Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01783834 on ClinicalTrials.gov